Seeking Alpha

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company...

Oppenheimer reiterates its "Outperform" rating on Gilead (GILD -0.2%), saying that the company has a number of under-appreciated opportunities related to its HIV combination treatments. Oppenheimer therefore reckons Gilead will generate more money from those medicines than expected.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector